After normalization and ANOVA F-value analysis, clinical factors including age, mismatch repair (MMR) status, preoperative TNM stage, tumour markers (CEA and CA19-9), genetic mutations (KRAS, NRAS, and BRAF) and invasion of adjacent tissues (LVI and PNI) were significantly different between the CRC LM (CRLM) group and the non-CRLM group (P <0.05). This evidence concerns the gene NRAS and colorectal carcinoma.